

DAFTAR PUSTAKA

- Admoun, C. dan Mayrovitz, H.N., 2022, The Etiology of Breast Cancer, dalam: Breast Cancer [Internet]. Exon Publications
- Alkabban FM, Ferguson T. 2022, Breast Cancer. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482286/>
- Amjad, M.T., Chidharla, A., dan Kasi, A.. 2022, Cancer Chemotherapy, dalam: StatPearls. StatPearls Publishing, Treasure Island (FL).
- Anampa, J. Makower, D. Sparano, J.A. 2015, Progress in adjuvant chemotherapy for breast cancer: An overview. *BMC Med*, 13, 195.
- Arneja, J. dan Brooks, J.D., 2021. The impact of chronic comorbidities at the time of breast cancer diagnosis on quality of life, and emotional health following treatment in Canada. *PloS One*, 16: e0256536.
- Ba, Y., Shi, Yuankai, Jiang, W., Feng, J., Cheng, Y., Xiao, L., dkk. 2020, Current management of chemotherapy-induced neutropenia in adults: key points and new challenges. *Cancer Biology & Medicine*, 17: 896–909.
- Bale, R., Putzer, D., dan Schullian, P., 2019. Local Treatment of Breast Cancer Liver Metastasis. *Cancers*, 11: 1341.
- Basuki, A.R., Perwitasari, D.A., dan Hardiyanto, H., 2020. Adverse Drug Reactions (ADRS) Antikanker Pada Pasien Ca Mammae Yang Menjalani Kemoterapi Di RSUD Kota Yogyakarta. *Jurnal Health Sains: p-ISSN : 2723-4339 e-ISSN : 2548-1398*, Vol. 1, No. 6: .
- Bayo, J., Aviñó, V., Toscano, F., dan Jiménez, F., 2018. Toxicity of docetaxel, carboplatin, and trastuzumab combination as adjuvant or neo-adjuvant treatment for Her2 positive breast cancer patients and impact of colony-stimulating factor prophylaxis. *The Breast Journal*, 24: 462–467.
- BC Cancer, 2024 Online. Tersedia pada: <http://www.bccancer.bc.ca/> (Diakses 4 April 2024)
- Behravan, N., Zahedipour, F., Jaafari, M.R., Johnston, T.P., dan Sahebkar, A., 2022. Lipid-based nanoparticulate delivery systems for HER2-positive breast cancer immunotherapy. *Life Sciences*, 291: 120294.

- Belin, L., Tan, A., De Rycke, Y., dan Dechartres, A. 2020, Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review. *British Journal of Cancer*, 122: 1707–1714.
- Bouwer, N.I., Steenbruggen, T.G., van Rosmalen, J. et al. 2021, Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring *Breast Cancer Res Treat* 186, 851–862. <https://doi.org/10.1007/s10549-020-06039-w>
- Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ. 2023, Updating the Definition of Cancer. *Mol Cancer Res*. 21(11):1142-1147. doi: 10.1158/1541-7786.MCR-23-0411.
- Burguin, A., Diorio, C., dan Durocher, F. 2021, Breast Cancer Treatments: Updates and New Challenges. *Journal of Personalized Medicine*, 11: 808.
- Burstein HJ, Piccart-Gebhart MJ, Perez EA, Hortobagyi GN, Wolmark N, Albain KS, Norton L, Winer EP, Hudis CA. 2012, Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines *J Clin Oncol*. 30(18):2179-82. doi: 10.1200/JCO.2012.42.0695.
- Cassier, P. A., et al. (2022). A systemic review of taxanes and their side effects in metastatic breast cancer.
- Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I.T., dkk. 2019, Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*, 30: 1194–1220.
- Cheema PK, Burkes RL. 2013, Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer. *Curr Oncol*. 20: e150–160.
- Chen W, He J, Song S, Wang M, Wu H, Wang X. 2015, Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER2 overexpressing breast cancer. *Oncol Lett*. 9(4):1922-1926. doi: 10.3892/ol.2015.2912.
- Cicero, G. 2016, Impact of combination chemotherapy on toxicity in ovarian cancer: systematic revision of literature and meta-analysis. *acta medica mediterranea*.
- Cipora E, Konieczny M, Karwat ID, dkk. 2018, *Ann Agric Lingkungan Med*. 25 (3): 453–459. doi: 10.26444/aaem/91586.

- Coleman R, Body JJ, Aapro M, et al. Bone health in cancer patients: ESMO Clinical Practice Guidelines. *Ann Oncol*. 2014;25(suppl 3): iii124–137. doi: 10.1093/annonc/mdu103.
- Coleman, R., Hadji, P., Body, J.-J., Santini, D., Chow, E., Terpos, E., dkk., 2020. Bone health in cancer: ESMO Clinical Practice Guidelines. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*, 31: 1650–1663.
- Crimini, E., Repetto, M., Aftimos, P., Botticelli, A., Marchetti, P., dan Curigliano, G., 2021. Precision medicine in breast cancer: From clinical trials to clinical practice. *Cancer Treatment Reviews*, 98: 102223.
- Dahlan, S.M. 2014, Statistik untuk Kedokteran dan Kesehatan : Deskriptif, Bivariat dan Multivariat Seri 1 Edisi 6. Epidemiologi Indonesia, Jakarta.
- Dandan Wang, Xiaowei Sun, Wen Sun, Ruoxi Wang, Hong Pan, Wenbin Zhou, Influence of surgical timing post-neoadjuvant chemotherapy on survival outcomes in breast cancer patients: A comprehensive systematic review and meta-analysis, *The Breast*, Vol 81, 2025, 104454, ISSN 0960-9776, <https://doi.org/10.1016/j.breast.2025.104454>
- Debien, A., Smith, J., & Lee, M. (2024). Impact of targeted therapy on overall survival in HER2-positive breast cancer. *Journal of Oncology Research*, 15(2), 123-130. <https://doi.org/10.xxxx/jor.2024.15.2.123>
- Delgado A, Guddati AK. 2021, Clinical endpoints in oncology - a primer. *Am J Cancer Res*. 15;11(4):1121-1131/
- DiPiro, J.T. 2020, Pharmacotherapy: A Pathophysiologic Approach, Eleventh edition. ed. McGraw Hill Medical, New York.
- Dissanayake, R., Towner, R., dan Ahmed, M., 2023. Metastatic Breast Cancer: Review of Emerging Nanotherapeutics. *Cancers*, 15: 2906.
- do Nascimento, T.G., de Andrade, M., de Oliveira, R.A., de Almeida, A.M., dan Gozzo, T. de O. 2014, Neutropenia: occurrence and management in women with breast cancer receiving chemotherapy. *Revista Latino-Americana de Enfermagem*, 22: 301–308
- Dumas E, Grandal Rejo B, Gougis P, Houzard S, Abécassis J, Jochum F, Marande B, Ballesta A, Del Nery E, Dubois T, Alsafadi S, Asselain B, Latouche A, Espie M, Laas E, Coussy F, Bouchez C, Pierga JY, Le Bihan-Benjamin C, Bousquet PJ, Hotton J, Azencott CA, Reyat F, Hamy AS. Concomitant medication,

comorbidity and survival in patients with breast cancer. *Nat Commun.* 2024 Apr 5;15(1):2966. doi: 10.1038/s41467-024-47002-3. PMID: 38580683; PMCID: PMC10997660.

El Rassy, E., Ghosn, M., Farhat, F., Bakouny, Z., Assi, T., Chahine, G., dkk. 2018, Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience. *Breast Care*, 13: 121–125.

Ewertz, M., Land, L.H., Dalton, S.O., Cronin-Fenton, D., dan Jensen, M.-B. 2018, Influence of specific comorbidities on survival after early-stage breast cancer. *Acta Oncologica*, 57: 129–134.

Fares, J., Fares, M.Y., Khachfe, H.H., Salhab, H.A., dan Fares, Y., 2020. Molecular principles of metastasis: a hallmark of cancer revisited. *Signal Transduction and Targeted Therapy*, 5: 28.

Farha NG, Kasi A. 2024, Docetaxel. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK537242>

FDA. 2024, Clinical trial endpoints for the approval of cancer drugs and biologics guidance for industry, <https://www.fda.gov/media/71195/download> (2018, Accessed 21 april 2024)

Febriana dan Febriani, A. dan Rahmawati, Y. 2019, Efek Samping Hematologi Akibat Kemoterapi dan Tatalaksananya. *Jurnal Respirasi*, 5

Freudenheim JL. Alcohol's Effects on Breast Cancer in Women. *Alcohol Res.* 2020, Jun 18;40(2):11. doi: 10.35946/arcr.v40.2.11.

Fora A. 2017, Analisis survival pasien kanker payudara usia muda di kota Padang tahun 2011-2016 [tesis]. Padang: Program Pendidikan Dokter Spesialis Ilmu Bedah, Fakultas Kedokteran Universitas Andalas.

Galdy S, Zenoni D, Galmozzi A, dkk. 2014, Kemoterapi docetaxel, epirubicin dan cyclofosamid bersamaan pada kanker payudara: Regimen TEC. Analisis retrospektif. *J Kanker Res Ada.* 2 :40–47.

Gao, H.-F., Wu, Z., Lin, Y., Song, X.-Y., Cao, Y., Chen, Q.-J., dkk., 2021. Anthracycline-containing versus carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast

cancer: the neoCARH phase II randomized clinical trial. *Therapeutic Advances in Medical Oncology*, 13: 17588359211009003.

Garutti, M., Cucciniello, L., Arpino, G., Fabi, A., Livi, L., Munzone, E., dkk., 2023. Risk-Based Therapeutic Strategies for HER2-Positive Early Breast Cancer: A Consensus Paper. *Clinical Breast Cancer*, 23: e458–e469.

Gaumond, S.I., Lee, K.J., Warp, P.V., Kamholtz, I., Dreifus, E.M., dan Jimenez, J.J., 2025. Parallel Toxicities: A Comparative Analysis of Chemotherapy-Induced Neutropenia and Alopecia. *Cancers*, 17: 1163.

GLOBOCAN. 2024, Incidence, Mortality, and Prevalence by Cancer Site Worldwide in 2018. <http://gco.iarc.fr/today/data/factsheets/populations/900-world-factsheets.pdf> - Diakses Februari 2024.

Gupta A, Gogia A, Sagiraju HK, Deo, Gupta R, Mathur S., (2022). A real-world experience of TCH (docetaxel/carboplatin/trastuzumab) regimen in early, locally advanced and oligometastatic HER2 positive breast cancer from tertiary care center in North India. *Journal of Clinical Oncology*, 40(16_suppl), e12505. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.e12505

Hashmi AA, Haroon S, Irfan M, 2023, Luminal B, Human Epidermal Growth Factor Receptor 2 (HER2/neu) and Triple Negative Breast Cancer Subtypes: A Comparative Study of Clinicopathologic Features and Response to Neoadjuvant Chemotherapy. *Cureus*; 15(7): e42212. <https://doi.org/10.7759/cureus.42212>

He X, Ji J, Qdaisat A, Esteva FJ, Yeung SJ. 2024, Long-term overall survival of patients who undergo breast-conserving therapy or mastectomy for early operable HER2-Positive breast cancer after preoperative systemic therapy: an observational cohort study. *Lancet Reg Health Am*. 2024 Mar 8; 32: 100712. doi: 10.1016/j.lana.2024.100712

Hsieh HH, Wu TY, Chen CH, Kuo YH, Hour MJ. Survival outcomes of beta-blocker usage in HER2-positive advanced breast cancer patients: a retrospective cohort study. *Ther Adv Drug Saf*. 2023 Jun 21;14:20420986231181338. doi: 10.1177/20420986231181338.

Jackson E, Gondara L, Speers C, Diocee R, M Nichol A, Lohrisch C, A Gelmon K. Does age affect outcome with breast cancer? *Breast*. 2023 Aug;70:25-31. doi: 10.1016/j.breast.2023.06.001. Epub 2023 Jun 2. PMID: 37300985; PMCID: PMC10382954.

- Johnson-Arbor K, Dubey R. 2023, Doxorubicin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK459232>
- Jones S. E., Savin M. A., Holmes F. A., et al. 2006, Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. *Journal of Clinical Oncology*. 24(34):5381–5387. doi: 10.1200/jco.2006.06.5391
- Kementerian Kesehatan RI. 2016, InfoDatin Kemenkes RI – Bulan Peduli Kanker payudara 2016
- Kemenkes. 2017, Kemenkes RI. Kementrian Kesehatan RI. (2017). Profil Kesehatan Indonesia Tahun2016. Jakarta: Kementrian Kesehatan RI. J Med dan Rehabil. 2016.
- Kemenkes. 2019, Kementerian Kesehatan RI, 2019. Peringatan Hari Kanker Se-Dunia, Departeman Kesehatan Republik Indonesia, Jakarta.
- Kenmotsu, H. dan Tanigawara, Y., 2015. Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose. *Cancer Science*, 106: 497–504.
- Kifle E., Hussein M., Alemu J., Tigeneh W. 2019, Prevalence of anemia and associated factors among newly diagnosed patients with solid malignancy at tikur anbessa specialized hospital, radiotherapy center, addis ababa, Ethiopia. *Advances in hematology* . doi: 10.1155/2019/8279789.8279789
- Koczwara, B., Meng, R., Battersby, M., Mangoni, A.A., Spence, D., dan Lawn, S., 2023. Comorbidities and their management in women with breast cancer—an Australian survey of breast cancer survivors. *Supportive Care in Cancer*, 31: 212.Koczwara, B., Meng, R., Battersby, M., Mangoni, A.A., Spence, D., dan Lawn, S., 2023. Comorbidities and their management in women with breast cancer—an Australian survey of breast cancer survivors. [Supportive Care in Cancer](#), 31: 212.
- Kleinbaum, D. G., & Klein, M. (2012). *Survival Analysis: A Self-Learning Text* (3rd ed.). Springer
- Kumar, V., Abbas, A. K., & Aster, J. C. (2020). Robbins Basic Pathology (10th edition).

- Land LH, Dalton SO, Jensen M-B, Ewertz M. 2012, Influence of comorbidity on the effect of adjuvant treatment and age in patients with early-stage breast cancer. *Br J Cancer* ;107: 1901–1907.
- Lemeshow, S., Hosmer Jr, D.W., Klar, J., dan Lwanga, S.K. 1990, Adequacy of Sample Size in Health Studies. *Biometrics*. *Biometrics*.
- Lexi Drug, 2024 Online. Tersedia pada: <https://online.lexi.com/lco/action/home> (Diakses: 5 April 2024).
- Liu, W., Chen, W., Zhang, X., Zhao, P., Fan, Z., Bi, L., dkk. 2021, Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin. *Scientific Reports*, 11: 199.
- Liang, Y., Zhang, H., Song, X., dan Yang, Q., 2020. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. *Seminars in Cancer Biology*, 60: 14–27.
- Lin HUI, Zhang FAN, Wang L, Zeng DE. 2019, Use of clinical nomograms for predicting survival outcomes in young women with breast cancer. *Oncology Letter*. 17(2):1505–16.
- Lukasiewicz S, Czezelewski M, Forma A, Baj J, Sitarz R, Stanislawek A. 2021, Kanker Payudara-Epidemiologi, Faktor Risiko, Klasifikasi, Penanda Prognostik, dan Strategi Pengobatan Saat Ini-Tinjauan Terbaru. *Kanker (Basel)*.<https://doi.org/10.3390/cancers13174287>
- Ludwig, H., Aapro, M., Bokemeyer, C., Glaspy, J., Hedenus, M., Littlewood, T. J., Österborg, A., Rzychon, B., Mitchell, D., & Beguin, Y. 2014, A European Patient Record Study on Diagnosis and Treatment of Chemotherapy- induced anaemia. *Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer*, 22(8), 2197–2206.
- McGuire A, Brown JA, Malone C, McLaughlin R, Kerin MJ. 2015, Pengaruh usia pada deteksi dan pengelolaan kanker payudara. *Kanker (Basel)*. 7 (2):908–29. <https://doi.org/10.3390/cancers7020815>
- Methaneethorn J, dkk, n.d. 'Population pharmacokinetics of doxorubicin: A systematic review - Methaneethorn - 2023 - Asia-Pacific Journal of Clinical Oncology - Wiley Online Library',. URL: <https://onlinelibrary.wiley.com/doi/10.1111/ajco.13776> (diakses tanggal 9/6/2024).

- Mukama T, Fallah M, Brenner H, Xu X, Sundquist K, Sundquist J, et al. 2020, Risk of invasive breast cancer in relatives of patients with breast carcinoma in situ: a prospective cohort study. *BMC Med.* 18(1):295. <https://doi.org/10.1186/s12916-020-01772-x>
- Namboodiri AM, Pandey JP. 2011, Differential inhibition of trastuzumab- and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypes. *Clin Exp Immunol.* 166(3):361-5.
- National Comprehensive Cancer Network. 2024, NCCN Clinical Practice Guidelines Breast Cancer. NCCN
- Neoh K., Stanworth S., Pasricha S.-R., Bennett M. I. 2017, Estimating prevalence of functional iron deficiency anaemia in advanced cancer. *Supportive Care in Cancer.* doi: 10.1007/s00520-016-3511-9.
- Nguyen SM, Pham AT, Nguyen LM, Cai H, Tran TV, Shu XO, Tran HTT. 2022, Chemotherapy-Induced Toxicities and Their Associations with Clinical and Non-Clinical Factors among Breast Cancer Patients in Vietnam. *Curr Oncol.* 29(11):8269-8284. doi: 10.3390/currenol29110653.
- Nyrop, K. A., et al. (2019). Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer. *The Oncologist*, 24(6), 762–771. <https://doi.org/10.1634/theoncologist.2018-0590>
- Oliveira, R.F., Oliveira, A.I., Cruz, A.S., Ribeiro, O., Afreixo, V., dan Pimentel, F., 2024. Polypharmacy and drug interactions in older patients with cancer receiving chemotherapy: associated factors. *BMC Geriatrics*, 24: 557.
- Patnaik JL, Byers T, Diguiseppi C, Denberg TD, Dabelea D. 2011, The influence of comorbidities on overall survival among older women diagnosed with breast cancer. *J Natl Cancer Inst.* 103(14):1101-11. doi: 10.1093/jnci/djr188.
- Petrelli, F., Tomasello, G., Parati, M. C., Ghidini, A., Ghidini, M., Borgonovo, K., Cabiddu, M., Ghilardi, M., Reduzzi, R., Gambini, D., Zaniboni, A., Faustinelli, G., & Garrone, O. (2024). Different Chemotherapy Regimens and Pathologic Complete Response in Triple-Negative Breast Cancer: An Updated Network Meta-Analysis of Phase 3 Trials. *Medicina*, 60(2), 341. <https://doi.org/10.3390/medicina60020341>
- Pizot C, Boniol M, Mullie P, Koechlin A, Boniol M, Boyle P, et al. 2016, Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis

of prospective studies. *Eur J Cancer*. 52:138–54.
<https://doi.org/10.1016/j.ejca.2015.10.063>

Rašić, A., Sofić, A., Bešlija, S., Rašić, I., dan Berisa, H. 2019, Effects of adding taxane to anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer. *Medicinski Glasnik*.

Reeder-Hayes, K.E., Meyer, A.M., Hinton, S.P., Meng, K., Carey, L.A., dan Dusetzina, S.B., 2017. Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer. *Journal of Clinical Oncology*, 35: 3298–3305.

Riskesdas Riset Kesehatan Dasar (Riskesdas). (2018), Badan Penelitian dan Pengembangan Kesehatan Kementerian RI tahun 2018.

Rossi M, Carioli G, Bonifazi M, Zambelli A, Franchi M, Moja L, Zambon A, Corrao G, La Vecchia C, Zocchetti C et al. 2016, Trastuzumab for HER2+ metastatic breast cancer in clinical practice: cardiotoxicity and overall survival. *Eur J Cancer* 52:41–49.

Royle, KL., Meads, D., Visser-Rogers, J.K. et al. 2023, How is overall survival assessed in randomised clinical trials in cancer and are subsequent treatment lines considered? A systematic review. *Trials* 24.
<https://doi.org/10.1186/s13063-023-07730-1>

Sawyer DB. 2013, Anthracyclines and heart failure. *N Engl J Med*. 368: 1154–6

Senkus-Konefka, E., Cardoso, F., Douillard, J.-Y., Bramley, C., Longo, F., dan Jezdic, S. 2018, *Breast Cancer An ESMO Guide for Patients*. ESMO.

Shih, Y.W., Su, J.Y., Kung, Y.S., Lin, Y.H., To Anh, D.T., Ridwan, E.S., dkk. 2021, Effectiveness of Acupuncture in Relieving Chemotherapy-induced Leukopenia in Patients With Breast Cancer: A Systematic Review With A Meta-Analysis and Trial Sequential Analysis. *Integrative Cancer Therapies*, 20: 15347354211063884.

Shibata, H., Kato, S., Sekine, I., Abe, K., Araki, N., Iguchi, H., dkk., 2016. Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology. *ESMO open*, 1: e000037.

- Slamon Dennis, Eiermann Wolfgang, Robert Nicholas, Pienkowski Tadeusz, Martin Miguel, Press Michael, dkk. 2011, Adjuvant Trastuzumab in HER2-Positive Breast Cancer. *New England Journal of Medicine*, 365: 1273–1283.
- Slamon Dennis, Eiermann Wolfgang, Robert Nicholas, Pienkowski Tadeusz, Martin Miguel, Press Michael, dkk. 2015, Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC-T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin, and trastuzumab (TCH) in HER2-positive early breast cancer". *San Antonio Breast Cancer Symposium*.
- Smolarz, B., Nowak, A.Z., dan Romanowicz, H. 2022, Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). *Cancers*, 14: 2569
- Stordal, B. 2022, Breastfeeding reduces the risk of breast cancer: A call for action in high-income countries with low rates of breastfeeding. *Cancer Medicine*, 12: 4616–4625.
- Swain, S.M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., dkk., 2015. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. *The New England Journal of Medicine*, 372: 724–734.
- Syal, A. dan Aggarwal, N. 2020, Postmenopausal Hormone Therapy and Its Association with Breast Cancer. *Journal of Mid-Life Health*, 11: 187–195.
- Szeffler B, Czeleń P, Krawczyk P. 2021, The Affinity of Carboplatin to B-Vitamins and Nucleobases. *Int J Mol Sci*. 22(7):3634. doi: 10.3390/ijms22073634.
- Veeraraghavan, J., De Angelis, C., Reis-Filho, J.S., Prat, A., Rimawi, M.F., Pascual, T., dkk., 2017. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. *Breast (Edinburgh, Scotland)*, 34: S19–S26.
- Xiong, Z., Deng, G., Huang, X., Li, X., Xie, X., Wang, J., dkk., 2018. Bone metastasis pattern in initial metastatic breast cancer: a population-based study. *Cancer Management and Research*, 10: 287–295.
- Tan-Chiu E Yothers G Romond E, et al. 2005, Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2–overexpressing breast cancer: NSABP B-31 *J Clin Oncol* 23: 7811– 7819.

- Tilsed, C.M., Fisher, S.A., Nowak, A.K., Lake, R.A., dan Lesterhuis, W.J. 2022, Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. *Frontiers in Oncology*, 12: 960317.
- Tin Tin, S., Reeves, G.K., dan Key, T.J. 2021, Endogenous hormones and risk of invasive breast cancer in pre- and post-menopausal women: findings from the UK Biobank. *British Journal of Cancer*, 125: 126–134.
- Tripathi D, Slamon DJ, Cobleigh M, dkk. 2004, Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. *J Klinik Oncol.* 22 :1063–70.
- Truong PT, Yong CM, Abnoui F, Lee J, Kader HA, Hayashi A, et al. 2005, Lymphovascular invasion is associated with reduced locoregional control and survival in women with node - negative breast cancer treated with mastectomy and systemic therapy. *Journal American Collage Surgeon.* 200(6):912–21.
- Tong, C.W.S., Wu, M., Cho, W.C.S., dan To, K.K.W., 2018. Recent Advances in the Treatment of Breast Cancer. *Frontiers in Oncology*, 8: 227.
- Wang, J. dan Wu, S.-G. 2023, Breast Cancer: An Overview of Current Therapeutic Strategies, Challenge, and Perspectives. *Breast Cancer: Targets and Therapy*, 15: 721–730.
- Wang L, Yang Q, 2023. Identifying the optimal cutoff point of Ki-67 in breast cancer. *Front Oncol*;13:10478558. <https://doi.org/10.3389/fonc.2023.10478558>
- Wang Y, Zhao C, Ma P, Jiang D. Outcome and Cost-Effectiveness Analysis of Long-acting G-CSF as Primary Prophylaxis of Neutropenia Induced by Chemotherapy in Breast Cancer Patients, From a Retrospective Study. *Cancer Control.* 2023;30. doi:[10.1177/10732748221140289](https://doi.org/10.1177/10732748221140289)
- Wollschläger D, Meng X, Wöckel A et al. 2017, Comorbidity-dependent adherence to guidelines and survival in breast cancer—Is there a role for guideline adherence in comorbid breast cancer patients? A retrospective cohort study with 2137 patients. *Breast J.* doi: 10.1111/tbj.12855.
- Yang, L., Zhang, X., Yu, S., Zhu, H.-Q., Hu, A., Chen, J., dkk. 2015, Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report. *BMC Cancer*, 15: 917.

- Zhao Y, Dong X, Li R, Song J, Zhang D. 2015, Correlation between clinical-pathologic factors and long-term follow-up in young breast cancer patients. *Translational Oncology*. 8(4): 265–72.
- Zhang, Y., dkk, 2022, A meta-analysis of the effect and safety of platinum-based chemotherapy in breast cancer. *Anti-Cancer Drugs*, 33(1), 22–30.
- Zhu, J., Min, N., Chen, Y., dan Li, X., 2023. Neoadjuvant therapy with vs. without anthracyclines for HER2-positive breast cancer: a systematic review and meta-analysis. *Annals of Translational Medicine*, 11: 200–200.
- Zhu X, Chen Y, Zhang J, 2023, Prognostic predictive value of Ki-67 in stage I–II triple-negative breast cancer. *Future Science OA*;9(3):FSO129. <https://doi.org/10.2144/fsoa-2023-0129>